Application of O-(4-diazo-3-[125I]iodobenzoyl)sucrose for the detection of the catabolic sites of low density lipoprotein.
The sites of degradation of human low density lipoprotein (LDL), are analyzed using the novel labelling compound O-(4-diazo-3-[125I]iodobenzoyl)sucrose (D125IBS). The decay from rat serum of D125IBS-labelled LDL is identical to the serum decay of conventionally iodinated (ICI method) LDL. The radioactivity derived from D125IBS-labelled LDL accumulates predominantly in the liver after intravenous injection and the hepatic radioactivity remains associated with the lysosomal compartment for an extended period of time, when compared to the radioactivity derived from conventionally iodinated LDL. It is concluded that the D125IBS labelling procedure is an interesting new tool to study the sites of catabolism of serum lipoproteins.
D000345:Affinity Labels; D000818:Animals; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes; D007463:Iodobenzoates; D007668:Kidney / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood* / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D000345:Affinity Labels; D007457:Iodine Radioisotopes; D007463:Iodobenzoates; D008077:Lipoproteins, LDL; C044133:O-(4-diazo-3-iodobenzoyl)sucrose